Literature DB >> 18235043

Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities.

Robert Sealy1, Wendy Chaka, Sherri Surman, Scott A Brown, Peter Cresswell, Julia L Hurwitz.   

Abstract

Recent clinical trials have shown that the presence of a robust human immunodeficiency virus type 1 (HIV-1)-specific T-cell response may not be sufficient to prevent or control HIV-1 infection. Studies of antigen processing in the context of infectious HIV-1 are therefore warranted. Envelope-specific, major histocompatibility complex class II-restricted murine T-cell hybridomas were tested for responsiveness to splenic antigen-presenting cells exposed to HIV-1-infected GHOST cells. Interleukin-2 assays showed that the presence of a peptide within HIV-1 did not ensure the reactivation of peptide-specific T cells. Further experiments defined the impact of gamma interferon-induced thiol reductase and cysteine proteases on the processing of HIV-1 peptides. The results highlight potential influences of peptide context on T-cell reactivation by HIV-1 and encourage the continued study of antigen processing as support for improved vaccine design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18235043      PMCID: PMC2292667          DOI: 10.1128/CVI.00412-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Control of antigen presentation by a single protease cleavage site.

Authors:  A N Antoniou; S L Blackwood; D Mazzeo; C Watts
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

Review 2.  The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation.

Authors:  T Y Nakagawa; A Y Rudensky
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

3.  T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry.

Authors:  Scott A Brown; Timothy D Lockey; Clive Slaughter; Karen S Slobod; Sherri Surman; Amy Zirkel; Ashutosh Mishra; Vishwajeeth R Pagala; Chris Coleclough; Peter C Doherty; Julia L Hurwitz
Journal:  AIDS Res Hum Retroviruses       Date:  2005-02       Impact factor: 2.205

4.  A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent.

Authors:  Mona K Tewari; Gomathinayagam Sinnathamby; Deepa Rajagopal; Laurence C Eisenlohr
Journal:  Nat Immunol       Date:  2005-02-13       Impact factor: 25.606

5.  Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

Authors:  Scott A Thomson; Angel B Jaramillo; Maryanne Shoobridge; Kerrie J Dunstan; Beth Everett; Charani Ranasinghe; Stephen J Kent; Ke Gao; Jill Medveckzy; Rosemary A Ffrench; Ian A Ramshaw
Journal:  Vaccine       Date:  2005-09-07       Impact factor: 3.641

6.  Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

Authors:  Xiaoyan Zhan; Louis N Martin; Karen S Slobod; Chris Coleclough; Timothy D Lockey; Scott A Brown; John Stambas; Mattia Bonsignori; Robert E Sealy; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2005-07-20       Impact factor: 3.641

7.  Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype.

Authors:  S A Brown; K S Slobod; S Surman; A Zirkel; X Zhan; J L Hurwitz
Journal:  AIDS Res Hum Retroviruses       Date:  2006-02       Impact factor: 2.205

Review 8.  The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.

Authors:  H Fred Clark; Paul A Offit; Stanley A Plotkin; Penny M Heaton
Journal:  Pediatr Infect Dis J       Date:  2006-07       Impact factor: 2.129

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

View more
  20 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Authors:  Gregory G Burrows; Roberto Meza-Romero; Jianya Huan; Sushmita Sinha; Jeffrey L Mooney; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2012-03-07       Impact factor: 3.584

5.  GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity.

Authors:  Hannah Phipps-Yonas; Vikki Semik; Karen Taraszka Hastings
Journal:  Eur J Immunol       Date:  2012-11-26       Impact factor: 5.532

Review 6.  Diverse cellular and organismal functions of the lysosomal thiol reductase GILT.

Authors:  Matthew P Rausch; Karen Taraszka Hastings
Journal:  Mol Immunol       Date:  2015-06-23       Impact factor: 4.407

Review 7.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

8.  Comparative quantitative mass spectrometry analysis of MHC class II-associated peptides reveals a role of GILT in formation of self-peptide repertoire.

Authors:  Branka Bogunovic; Priya Srinivasan; Yumi Ueda; York Tomita; Maja Maric
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

10.  GILT is a critical host factor for Listeria monocytogenes infection.

Authors:  Reshma Singh; Amanda Jamieson; Peter Cresswell
Journal:  Nature       Date:  2008-09-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.